Professor Katie Flanagan,
Infectious Diseases Specialist and Clinical Professor, University of Tasmania.
Her talk will discuss the platform technologies being used to design COVID-19 vaccines, candidates in preclinical and clinical trials and phase 3 trial efficacy results. It will then discuss the progress globally with COVID-19 vaccine rollout and the Australian COVID-19 strategy and program in more detail. It will conclude with discussing next-generation vaccines including those against emerging SARS-CoV-2 variants.